Previous 10 | Next 10 |
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees a heavy dose of healthcare companies presenting at investor con...
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that management will prese...
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that management will present a c...
Investors should not be able to justify seeing Kaleido (KLDO) with an enterprise value of $462 million. There are two reasons. Firstly, peers with more advanced stage of development and more product candidates are trading with an enterprise value of $77-$245 million. In addition, the market op...
Quick Take Kaleido Biosciences ( OTC:KLDO ) intends to raise $100 million from the sale of its common stock, per an amended registration statement . The company is developing microbiome-centric treatment candidates for hyperammonemia and other urea cycle disorders. KLDO is seeking a hig...
Evelo Biosciences, Inc. (EVLO) Q4 2018 Results Conference Call February 14, 2019 08:30 AM ET Company Participants Stefan Riley - IR Simba Gill - CEO Duncan McHale - Chief Medical Officer Mark Bodmer - Chief Scientific Officer Jonathan Poole - CFO Conference Call Participa...
-- First Patient Dosed in University of Chicago Phase 2a Trial of EDP1503 in Metastatic Melanoma -- -- Preclinical Studies Have Shown Non-replicating Monoclonal Microbials Maintain Activity: EDP1867 in Development -- -- Initial Clinical Data for EDP1066 in Atopic Dermatitis and Psorias...
CAMBRIDGE, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that it will host a conference ca...
- Initial Clinical Data Anticipated in Second Half of 2020 - CAMBRIDGE, Mass., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a biotechnology company developing monoclonal microbials, a new modality of oral biologic medicines, today an...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...